



BeiGene Secures 600 Million RMB (\$97 Million US) Financing

– 4 novel oncology candidates expected to be in clinical trials by end of 2015, including PD-1 monoclonal antibody –

Grand Cayman, May 13th, 2015,— BeiGene Ltd., an innovative oncology company focused on developing targeted and immuno-oncology therapeutics, today announced the successful completion of a \$US 97 million financing. The financing was co-led by existing investors, including Hillhouse Capital and an undisclosed blue chip U.S. public investment fund specializing in life sciences. CITICPE, together with all other existing investors of BeiGene, joined the financing, continuing to show confidence in the company. In addition, this financing included new investments from Fidelity Management & Research Company, T. Rowe Price & Associates, Rock Springs Capital Management, and Boxer Capital of Tavistock Life Sciences.

BeiGene plans to use the proceeds from this financing to support the continued development of its oncology drug candidates, to expand its global clinical development team and capabilities, and to strengthen its drug product manufacturing and CMC capabilities.

“We are very pleased with the support and commitment of our existing investors and the participation of such high caliber new investors. We are happy that these firms recognize the unique potential of our company, and we look forward to working with them as we progress with our rapidly-expanding clinical pipeline,” said John V. Oyler, CEO of BeiGene.

“Our translational research platform continues to produce exciting targeted and immuno-oncology candidates with global best-in-class potential, which we believe may become crucial elements in a rapidly changing oncology landscape that points toward combination therapies in order to provide patients with meaningful solutions.”

BeiGene is currently investigating three small molecule inhibitors in Phase 1 clinical development: BGB-3111, an investigational, oral, highly selective and potent inhibitor of Bruton tyrosine kinase (BTK); BGB-283, a second-generation B-RAF inhibitor; and BGB-290, a poly (ADP-ribose) polymerase (PARP) inhibitor. The company is also pursuing additional preclinical programs, including BGB-108, a highly potent and potentially differentiated PD-1 monoclonal antibody candidate which is expected to enter the clinic in 2015.

“BeiGene continues to differentiate itself, not only through its top-tier biology and unique geographical advantages, but also by consistent clinical execution across a range of different programs and an understanding of the rapidly-evolving oncology treatment paradigm,” said Michael Yi, partner at Hillhouse Capital. “We are excited to continue

supporting the company with this financing, and we look forward to all of the developments in the coming years.”

“China is increasingly involved in research and development of global new drugs with its cost advantage and sufficient educated human resources. Beigene demonstrates a unique combination of world-class drug discover capability and China R&D platform” said Tang Ke, Vice President at CITICPE. “We are happy to support Beigene making further progress.”

About BeiGene Ltd.

BeiGene is an innovative oncology R&D company focused on discovering, developing and commercializing targeted and immuno-oncology therapeutics through a novel translational research platform that leverages our strong internal oncology biology expertise with unique access to a large number of patient-derived tumor biopsies. With a team of over 170 scientists and staff, its pipeline is comprised of novel oral small molecules and monoclonal antibodies to create compelling combination solutions for cancer. BeiGene Ltd. is a Cayman Islands exempted company that is an investor in and collaborator with BeiGene (Beijing), Co. Ltd. For more information, please visit our website at www.beigene.com.

Media/Investor Contact:

Xin Huang
BeiGene
+86 185-1406-3050
pr@beigene.com